Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ADPT

Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies Corporation
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ADPT
日付受信時刻ニュースソース見出しコード企業名
2024/05/0805 : 30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/05/0805 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/05/0805 : 05GlobeNewswire Inc.Adaptive Biotechnologies Reports First Quarter 2024 Financial ResultsNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/04/1805 : 05GlobeNewswire Inc.Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024NASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/04/0305 : 05GlobeNewswire Inc.Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 RevenueNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/2721 : 30GlobeNewswire Inc.Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024NASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/03/0709 : 38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/02/2306 : 05GlobeNewswire Inc.Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/02/1506 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/02/1506 : 05GlobeNewswire Inc.Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/01/3006 : 05GlobeNewswire Inc.Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024NASDAQ:ADPTAdaptive Biotechnologies Corporation
2024/01/3006 : 00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/12/2806 : 05GlobeNewswire Inc.Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/12/0922 : 30GlobeNewswire Inc.Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual MeetingNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/12/0521 : 30GlobeNewswire Inc.Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual MeetingNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/11/2107 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/11/1006 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/11/1006 : 05GlobeNewswire Inc.Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/11/0721 : 30GlobeNewswire Inc.Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy PipelineNASDAQ:ADPTAdaptive Biotechnologies Corporation
2023/11/0305 : 05GlobeNewswire Inc.Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023NASDAQ:ADPTAdaptive Biotechnologies Corporation
 Showing the most relevant articles for your search:NASDAQ:ADPT

最近閲覧した銘柄

Delayed Upgrade Clock